ADMA

ADMA Biologics Inc

Add to Watchlist

Advanced Chart

16.030

+0.12(0.754%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.040

Open

15.910

VWAP

15.88

Vol

3.18M

Mkt Cap

3.83B

Low

15.680

Amount

50.53M

EV/EBITDA(TTM)

23.11

Total Shares

231.81M

3.78B

EV/OCF(TTM)

49.27

P/S(TTM)

8.27

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

146.40M

+27.52%

0.190

+72.73%

137.17M

+16.69%

0.173

-62.32%

131.20M

+9.48%

0.153

+2.22%

Estimates Revision

The market is revising Downward the revenue expectations for ADMA Biologics, Inc. (ADMA) for FY2025, with the revenue forecasts being adjusted by -0.27% over the past three months. During the same period, the stock price has changed by -10.30%.

Revenue Estimates for FY2025

Revise Downward

-0.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.47%

In Past 3 Month

Stock Price

Go Down

-10.30%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 16.030

Low

32.00

Averages

32.00

High

32.00

Current: 16.030

Low

32.00

Averages

32.00

High

32.00

Raymond James

Strong Buy

maintain

$25 -> $32

2025-05-08

Reason

Raymond James

Price Target

$25 -> $32

2025-05-08

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Adma Biologics to $32 from $25 and keeps a Strong Buy rating on the shares. Adma's Q1 missed slightly from a non-recurring event and higher spend, but all the fundamentals are trending positively and 2025-2026 guidance was raised still with a lot of room for upside, the analyst tells investors in a research note. The firm adds that tariffs are "not an issue" for Adma.

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$25

2025-03-04

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$25

2025-03-04

Reiterates

Buy

Reason

Raymond James

Elliot Wilbur

Strong Buy

Maintains

$18 → $25

2024-11-08

Reason

Raymond James

Elliot Wilbur

Price Target

$18 → $25

2024-11-08

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$18 → $26

2024-11-08

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$18 → $26

2024-11-08

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$18

2024-10-14

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$18

2024-10-14

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for ADMA Biologics Inc (ADMA.O) is 22.21, compared to its 5-year average forward P/E of -0.53. For a more detailed relative valuation and DCF analysis to assess ADMA Biologics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.53

Current PE

22.21

Overvalued PE

51.18

Undervalued PE

-52.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.74

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

19.41

Undervalued EV/EBITDA

0.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.31

Current PS

0.00

Overvalued PS

6.89

Undervalued PS

1.73